van de Woestijne AP, van der Graaf Y, de Bakker PIW, et al. Rs964184 (APOA5-A4-C3-A1) is related to elevated plasma triglyceride levels, but not to an increased risk for vascular events in patients with clinically manifest vascular disease. PLoS One. 2014;9(6):e101082. doi:10.1371/journal.pone.0101082
Lundh M, Galbo T, Poulsen SS, Mandrup-Poulsen T. Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats. Diabetes Obes Metab. 2015;17(7):703-7. doi:10.1111/dom.12470
Ho JE, Larson MG, Ghorbani A, et al. Metabolomic Profiles of Body Mass Index in the Framingham Heart Study Reveal Distinct Cardiometabolic Phenotypes. PLoS One. 2016;11(2):e0148361. doi:10.1371/journal.pone.0148361
Kong X, Banks A, Liu T, et al. IRF4 is a key thermogenic transcriptional partner of PGC-1α. Cell. 2014;158(1):69-83. doi:10.1016/j.cell.2014.04.049
Dai N, Zhao L, Wrighting D, et al. IGF2BP2/IMP2-Deficient mice resist obesity through enhanced translation of Ucp1 mRNA and Other mRNAs encoding mitochondrial proteins. Cell Metab. 2015;21(4):609-21. doi:10.1016/j.cmet.2015.03.006
Yassour M, Lim MY, Yun HS, et al. Sub-clinical detection of gut microbial biomarkers of obesity and type 2 diabetes. Genome Med. 2016;8(1):17. doi:10.1186/s13073-016-0271-6
Hung CM, Calejman CM, Sanchez-Gurmaches J, et al. Rictor/mTORC2 loss in the Myf5 lineage reprograms brown fat metabolism and protects mice against obesity and metabolic disease. Cell Rep. 2014;8(1):256-71. doi:10.1016/j.celrep.2014.06.007
Liu J, Lee J, Hernandez MAS, Mazitschek R, Ozcan U. Treatment of obesity with celastrol. Cell. 2015;161(5):999-1011. doi:10.1016/j.cell.2015.05.011
Arora P, Wu C, Hamid T, et al. Acute Metabolic Influences on the Natriuretic Peptide System in Humans. J Am Coll Cardiol. 2016;67(7):804-12. doi:10.1016/j.jacc.2015.11.049